Physician profile
Timothy Fuller
NPI 1104153063
$8,709.76
in general payments reported to CMS, 2019-2025
26 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $1,373 · 2021: $1,239 · 2022: $725 · 2023: $758 · 2024: $1,618 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,288 · Travel and Lodging: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.11 |
| Travel and Lodging | $421.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $1,491.13 | 2021-2024 | Torus Stent Graft System, Endocross Device, Afx2 Bifurcated Endograft System |
| W. L. Gore & Associates, INC. | $1,272.97 | 2021-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Viabahn Vbx Balloon Expandable Endo, Gore Viabahn Endoprosthesis With Heparin |
| Silk Road Medical, INC. | $1,228.09 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Cardiovascular Systems INC. | $1,071.92 | 2019-2023 | Diamondback Peripheral |
| Abbott Laboratories | $1,059.38 | 2019-2025 | Xact, Diamondback Peripheral, Jeti Peripheral Catheter |
| Penumbra, INC. | $486.17 | 2020-2025 | Penumbra System |
| Medtronic, INC. | $281.00 | 2021-2025 | Endurant Iis, Hawkone, Heli-Fx Endoanchor System |
| Inari Medical, INC. | $274.97 | 2020-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Angiodynamics, INC. | $272.18 | 2025 | Venacure 1470 Pro, Smart Port Ct |
| Bard Peripheral Vascular, INC. | $179.57 | 2020-2023 | Venovo |
| Janssen Pharmaceuticals, INC | $179.49 | 2020-2022 | |
| Shockwave Medical, INC | $155.08 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Mallinckrodt Enterprises LLC | $128.64 | 2019 | |
| Bolton Medical INC | $125.16 | 2020 | |
| Reflow Medical INC | $120.00 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $108.45 | 2020-2021 | |
| Lemaitre Vascular, INC. | $55.16 | 2023 | Artegraft Vascular Graft |
| E.R. Squibb & Sons, L.L.C. | $39.19 | 2022-2023 | Eliquis |
| Organogenesis INC. | $30.91 | 2023-2024 | Puraply |
| Baxter Healthcare | $30.48 | 2022 | |
| Terumo Medical Corporation | $27.16 | 2021-2023 | Metacross Otw, R2p Misago, Glidewire |
| Smith+Nephew, INC. | $24.96 | 2025 | Stravix |
| Ethicon US, LLC | $22.81 | 2024 | Vistaseal, Surgicel Nu-Knit, Prolene |
| Paratek Pharmaceuticals, INC. | $15.84 | 2023 | Nuzyra |
| Boston Scientific Corporation | $15.60 | 2024 | |
| Merck Sharp & Dohme LLC | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.